Born with Autism (formerly classified as Asperger syndrome), Tyler B. Searle has been obsessed with storytelling since he was old enough to speak. He gravitated towards fairy tales, mythology, the ...

Monkfish, an unattractive but tasty fish, has seen its market value plummet, hurting Rhode Island's fishing industry. A new program called Sea to Schools is introducing monkfish sliders to ...

Bandai Namco Filmworks has unveiled a new trailer for “Mobile Suit Gundam Hathaway: The Sorcery of Nymph Circe,” the second chapter in the Hathaway film trilogy, ahead of its U.S. theatrical opening ...

Edmunds says Geely's Galaxy M9 - costing $25,000 in China - rivals much pricier U.S. models M9 offers a 30-inch infotainment screen, built-in fridge, 808-mile driving range US consumers show rising ...

'Mobile Suit Gundam Hathaway: The Sorcery of Nymph Circe' has been out in Japan since the start of the year, but U.S. audiences will finally get to see it May 15. Reading time 2 minutes After months ...

Google Search has started testing the use of AI to replace headlines and website titles, a change that seems both unnecessary and a slippery slope. As spotted by The Verge over the past “few months,” ...

Fantasy is one of entertainment’s most diverse genres. With stories that take fans to rich and exciting worlds — some like our own, some very different — there is room for truly endless characters, ...

A new light-based sensor can spot incredibly tiny amounts of cancer biomarkers in blood, raising the possibility of earlier and simpler cancer detection. The technology merges DNA nanotechnology, ...

Feb 27 (Reuters) - Flagship-backed Generate Biomedicines' shares fell more than 6% in their Nasdaq debut on Friday, giving the drug developer a valuation of $1.91 billion, as lingering market ...

Despite wide availability of biologic drugs for asthma, use of these injectable medicines remains low — patients just dislike frequent injections. Generate Biomedicine’s lead drug candidate could ...

Generate:Biomedicines is the latest biotech to benefit from a renewed appetite from investors for publicly listed drug developers. Generate—which will list its stock on the Nasdaq this morning under ...

Generate Biomedicines Inc., a biotechnology firm using artificial intelligence in drug development, is seeking to raise as much as $425 millon in an initial public offering, as listing activity in the ...